Allakos Announces Clinical Update and Third Quarter 2018 Financial Results
November 08, 2018 16:01 ET
|
Allakos Inc.
-- Clinical data expected in early first quarter 2019 -- SAN CARLOS, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the...
Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
October 08, 2018 08:00 ET
|
Allakos Inc.
SAN CARLOS, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and...
Allakos Announces Second Quarter 2018 Financial Results
August 29, 2018 16:01 ET
|
Allakos Inc.
SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and...
Allakos Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 24, 2018 08:00 ET
|
Allakos Inc.
SAN CARLOS, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various...
Allakos Announces Pricing of Initial Public Offering
July 19, 2018 07:00 ET
|
Allakos Inc.
SAN CARLOS, Calif., July 19, 2018 (GLOBE NEWSWIRE) -- Allakos Inc., (Nasdaq:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various...
Allakos Highlights Data Demonstrating Potential of AK002 to Rapidly Deplete Eosinophils at 2018 AAAAI/WAO Joint Congress
March 05, 2018 09:45 ET
|
Allakos
-- Phase 1 data demonstrate AK002 rapidly depletes blood eosinophils after a single dose -- -- AK002 may provide an important new option in treating chronic allergic and inflammatory diseases such as...
Allakos Secures $100 Million In Series B Financing
December 13, 2017 09:00 ET
|
Allakos
Proceeds will support advancement of AK002 in five disease areas Lead clinical program evaluating AK002 in eosinophilic gastroenteritis, an inflammatory gastrointestinal disease SAN CARLOS,...
Allakos Announces Additions to Senior Leadership Team
August 15, 2017 10:01 ET
|
Allakos
Board of Directors appoints Robert Alexander as CEO and Adam Tomasi as COO & CFO Allakos plans to initiate a broad, multi-indication clinical program with AK002 in 2017 SAN CARLOS, Calif., Aug. ...